03 jan: FLSmidth/Carnegie: Løfter til "køb"
03 jan: Bavarian får penge i kassen før tid - NY
03-01-2017 11:24:26

Bavarian Nordic Upgrades its Expectations for 2016 Year-end Cash Preparedness

Relateret indhold
16 mar - 
Aktier/middag: Genmab rykker igen mod rekord i grønt ma..
16 mar - 
Bavarian/Jyske: Endnu et løftet kursmål efter regnskab ..
16 mar - 
Aktier/åbning: Lille plus med Nets og Genmab i toppen
Relateret debat
27 mar - 
Har kigget i krystalkuglen ....
27 mar - 
Hvorfor tror du det?
27 mar - 
Aktien stryger forbi kurs 359 i morgen ...... :)

COPENHAGEN, Denmark, January 3, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the Company upgrades its expectations for the 2016 year-end cash preparedness from approximately DKK 1,900 million to approximately DKK 2,300 million. The upgrade is primarily a result of payments for IMVAMUNE deliveries, which have been received earlier than expected and to a minor extent the increased USD exchange rate as well as deferred investments. For 2016, the Company maintains its expectations for revenues of approximately DKK 1,000 million and a break-even result before interest and tax.

The full financial statements for 2016 will be published in the annual report on March 15, 2017.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 01 / 2017

2017-01-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2017-01-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
26 mar
BAVA
Det ville være dejligt - men det tror jeg ikke, vi er vist i en periode hvor den lige skal konsulere..
10
22 mar
BAVA
Det var en shorter, som bankede den ned her til eftermiddag. Bogle investment. Kommer ind med et sho..
7
21 mar
BAVA
Der er jo intet nyt - når en aktier falder meget går jeg altid direkte på OMX for at se om der er ko..
7
21 mar
BAVA
Her er der lidt læsning til aften kaffen..   http://www.bavarian-nordic.com/media/239960/2016-ar-sum..
7
24 mar
BAVA
Den anden store shorter marshall har reduceret med 0,12 %. Strøjer
6
23 mar
BAVA
Millennium reducerer deres short fra 1,28 til 1,16 Reduceret fra 1,40 til 1,16 fra d. 19 til i går. ..
6
21 mar
BAVA
hvad mange private ofte glemmer ved shorts, er det meget simple at: Ved køb af en aktie, kan du max ..
6
27 mar
BAVA
Shorter har reduceret med 0,07% i dag - dvs shorterne over 0,5% ligger nu på 6,37%   https://oasm.fi..
5
23 mar
BAVA
Ja aktien har en kæmpe upside og en relative lille downside, et lille pust så er aktien over kurs 40..
4
27 mar
BAVA
Det er netop i dette tilfælde hvor shorter er positivt. De holder i øjeblikket hånden under aktien, ..
3

Aktier/middag: Mærsk tager bundplacering i middagshandlen

27-03-2017 12:00:29
A.P. Møller-Mærsks aktier falder mandag middag og tager bundplaceringen i C20 Cap-indekset. Dermed følger aktien den trend, der ligeledes ses ude i Europa, hvor råvaresektoren samlet ligger til et fald på 1,5 pct. i det brede europæiske Stoxx 600-indeks.- Vi ser, at olie og råvarer sætter sig lidt i dag, og det slår igennem hos Mærsk, siger Mads Zink, der chefhandler i Danske Bank, til Ritzau Fina..

Novo mister tronen som tungeste aktie i C20 Cap

27-03-2017 09:40:18
Novo Nordisk har ikke længere den største indflydelse på udviklingen i det toneangivende danske aktieindeks, C20 Cap.Medicinalgiganten fra Bagsværd er faldet ned på andenpladsen i vægtningen i indekset trods en markedsværdi, der fortsat er klart den højeste blandt de børsnoterede danske selskaber.Danske Bank er den nye på topplaceringen med en vægt på 14,5 pct., mens Novo-aktien er faldet til 12,9..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo mister tronen som tungeste aktie i C20 Cap
2
Aktier/tendens: Trump-forlis kan sende aktier i minus
3
Aktier/Nykredit: Ser risiko for let dukkert på aktiemarkedet
4
Vind/Siemens: Hele vindindustrien vil få glæde af skatterabat
5
Vestas fejrer ny vingefabrik i Indien med hensigtsaftaler

Relaterede aktiekurser

Bavarian Nordic A/S 347,50 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
28. marts 2017 04:35:19
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB1 - 2017-03-28 04:35:19 - 2017-03-28 04:35:19 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x